SCHEMBL29820164

SCHEMBL29820164

CC(C)c1ccc(C(N)c2cccnc2NC(=O)OC(C)(C)C)cc1F

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
P2RY1 P47900 1/20 0.39
L3MBTL1 Q9Y468 2/20 0.38
ALDH1A1 P00352 1/20 0.38
FAAH O00519 1/20 0.37
CYP17A1 P05093 1/20 0.35
SYK P43405 1/20 0.35
MAPK1 P28482 1/20 0.35
S1PR3 Q99500 1/20 0.35
METAP1 P53582 1/20 0.35
AAK1 Q2M2I8 3/20 0.34
CYP3A4 P08684 1/20 0.33
CYP3A5 P20815 1/20 0.33
P2RX3 P56373 1/20 0.33
NAMPT P43490 1/20 0.33
RECQL P46063 1/20 0.33
MEN1 O00255 1/20 0.33
NPC1 O15118 1/20 0.33
RAB9A P51151 1/20 0.33
KMT2A Q03164 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24666063 1.00 P2RY1 (0.39) P2RY1L3MBTL1ALDH1A1FAAHCYP17A1
SCHEMBL32665001 0.86 NPC1 (0.42) L3MBTL1ALDH1A1MAPK1METAP1NAMPT
SCHEMBL27289163 0.86 NPC1 (0.42) L3MBTL1ALDH1A1MAPK1METAP1NAMPT
SCHEMBL29820165 0.83 L3MBTL1 (0.35) P2RY1L3MBTL1ALDH1A1FAAHCYP17A1
SCHEMBL24666066 0.83 L3MBTL1 (0.35) P2RY1L3MBTL1ALDH1A1FAAHCYP17A1
SCHEMBL20901331 0.81 METAP1 (0.44) P2RY1L3MBTL1ALDH1A1CYP17A1SYK
SCHEMBL24666068 0.76 HTRA1 (0.38) S1PR3CYP3A4CYP3A5
SCHEMBL29230940 0.75 P2RY1 (0.42) P2RY1L3MBTL1ALDH1A1FAAHS1PR3
SCHEMBL2260258 0.74 METAP1 (0.46) L3MBTL1CYP17A1SYKMETAP1AAK1
SCHEMBL14489127 0.70 CYP17A1 (0.48) L3MBTL1ALDH1A1CYP17A1AAK1P2RX3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12534453-B2 Inhibitors of glycogen synthase 1 (GYS1) and methods of use thereof MAZE THERAPEUTICS, INC. (US) 2026-01-27 US disclosed
US-20240246939-A1 INHIBITORS OF GLYCOGEN SYNTHASE 1 (GYS1) AND METHODS OF USE THEREOF HERCULES CAPITAL, INC., AS AGENT 2024-07-25 US disclosed
EP-4308095-A1 INHIBITORS OF GLYCOGEN SYNTHASE 1 (GYS1) AND METHODS OF USE THEREOF Maze Therapeutics, Inc. (US) 2024-01-24 EP disclosed
US-11814367-B2 Inhibitors of glycogen synthase 1 (GYS1) and methods of use thereof MAZE THERAPEUTICS, INC. (US) 2023-11-14 US disclosed
US-20230104740-A1 INHIBITORS OF GLYCOGEN SYNTHASE 1 (GYS1) AND METHODS OF USE THEREOF HERCULES CAPITAL, INC., AS AGENT 2023-04-06 US disclosed
WO-2022198196-A1 INHIBITORS OF GLYCOGEN SYNTHASE 1 (GYS1) AND METHODS OF USE THEREOF MAZE THERAPEUTICS, INC. (US) 2022-09-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11814367-B2 Inhibitors of glycogen synthase 1 (GYS1) and methods of use thereof GYS2, GYS1, PYGL P2RY1 3736/4885L3MBTL1 1532/4885ALDH1A1 2458/4885
US-20230104740-A1 INHIBITORS OF GLYCOGEN SYNTHASE 1 (GYS1) AND METHODS OF USE THEREOF GYS2, GYS1, PYGL P2RY1 3736/4885L3MBTL1 1532/4885ALDH1A1 2458/4885
US-12534453-B2 Inhibitors of glycogen synthase 1 (GYS1) and methods of use thereof GYS1, GYS2, GBA1 P2RY1 3534/4885L3MBTL1 656/4885ALDH1A1 2276/4885
US-20240246939-A1 INHIBITORS OF GLYCOGEN SYNTHASE 1 (GYS1) AND METHODS OF USE THEREOF GYS2, GYS1, PYGL P2RY1 3736/4885L3MBTL1 1532/4885ALDH1A1 2458/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.